[Changes in lysozyme activity in hyperlipidemia and atherosclerosis in animals].
The lysocyme activity in blood serum and liver hemogenate of rats and rabbits at hyperlipidemia and atherosclerosis and its treatment with some new compounds or chemicals has been studied. A change of natural resistance of the body at hyperlipidemia and atherosclerosis characterized by the increase of serum lysocyme activity has been found. Preparations used in this work exerted mobilizing effect on the level of serum lysocyme activity but their influence on the functional state of the liver was different.
D000276:Adjuvants, Immunologic; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000201:enzymology*; D004789:Enzyme Activation / Q000187:drug effects; D006937:Hypercholesterolemia / Q000201:enzymology; D006949:Hyperlipidemias / Q000188:drug therapy / Q000201:enzymology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007113:Immunity, Innate / Q000187:drug effects; D008099:Liver / Q000201:enzymology; D009113:Muramidase / Q000276:immunology / Q000502:physiology*; D009525:Niacin / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D014280:Triglycerides / Q000097:blood
D000276:Adjuvants, Immunologic; D000960:Hypolipidemic Agents; D014280:Triglycerides; D009525:Niacin; D009113:Muramidase
Izmenenie aktivnosti lizotsima pri giperlipidemii i ateroskleroze u zhivotnykh.